ImmunityBio, Inc.
IBRX
Ранг среди акций
#2131
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Цена акции
$9.08
Последняя синхронизация: 2026-10-16
Рыночная капитализация
$9.62B
Изменение (1 день)
-9.25%
Изменение (1 год)
278.13%
Страна
US
Торговля ImmunityBio, Inc. (IBRX)
Категория
Healthcare
Операционная маржа для ImmunityBio, Inc. (IBRX)
Операционная маржа на October 2026 TTM: -151.88%
Согласно последним финансовым отчетам и цене акций ImmunityBio, Inc., текущая операционная маржа (TTM) составляет -151.88%. В конце 2023 она составила -58,239.55%.
История операционной маржи ImmunityBio, Inc. с 2013 по 2026
Операционная маржа на конец каждого года
| Год | Операционная маржа | Изменить |
|---|---|---|
| 2026 (TTM) | -151.88% | -93.49% |
| 2024 | -2,334.23% | -95.99% |
| 2023 | -58,239.55% | -60.21% |
| 2022 | -146,374.17% | 313.93% |
| 2021 | -35,361.88% | -3.14% |
| 2020 | -36,509.09% | 414.51% |
| 2019 | -7,095.87% | -96.61% |
| 2018 | -209,338.30% | -4.96% |
| 2017 | -220,266.67% | -22.15% |
| 2016 | -282,954.55% | 179.55% |
| 2015 | -101,218.64% | 10,344.49% |
| 2014 | -969.11% | 156.26% |
| 2013 | -378.17% | 0.00% |
Операционная маржа для аналогичных компаний или конкурентов
| Компания | Операционная маржа | Разница в операционной марже | Страна |
|---|---|---|---|
| 38.59% | -100.25% |
US
|
|
| -149.01% | -99.02% |
US
|
|
| 25.57% | -100.17% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.19% |
NL
|
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.